# US 10,441,643 B2 · Methods and materials for treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,441,643 B2
- Document ID: US10441643B2
- Status: Granted
- Kind: B2
- Application number: 15/126,333
- Filed: 2015-03-19
- Published: 2017-03-23
- Granted: 2019-10-15
- Earliest claimed: 2014-03-19
- Assignees: Mayo Foundation for Medical Education and Research; University of Leeds
- Applicants: Mayo Foundation for Medical Education and Research; University of Leeds
- Inventors: Jose S. Pulido; Richard G. Vile; Timothy J. Kottke; Jill M. Thompson; Rosa Maria Diaz; Christine Marie Pulido; Alan A. Melcher; Peter Selby
- Web page: https://patentgrep.com/patent/US10441643B2

## CPC

- A61K 39/0011: {Cancer antigens}
- A61K 35/766: Rhabdovirus, e.g. vesicular stomatitis virus
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/001128: {CD44 not IgG}
- A61K 39/001134: {Transforming growth factor [TGF]}
- A61K 39/001162: {Kinases, e.g. Raf or Src}
- A61K 39/001164: {GTPases, e.g. Ras or Rho}
- A61P 35/00: Antineoplastic agents
- C07K 14/82: Translation products from oncogenes
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2818: {against CD28 or CD152}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2760/20243: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This document provides methods and materials for treating cancer. For example, methods and materials for treating cancer using combinations of antigens are provided. For example, VSV vectors designed to express a GNAQ antigen, a TYRP1 antigen, and an N-RAS antigen can be used to reduce the number of cancer cells (e.g., uveal melanoma cells) within a mammal (e.g., a human). In some cases, VSV vectors designed to express a BRAF antigen, a TOPO-11a antigen, and a YB-I antigen can be used to reduce the number of cancer cells (e.g., skin melanoma cells) within a mammal (e.g., a human). The composition can comprise less than 50 separate nucleic acid molecules.

## Claims

### Claim 1

A composition comprising one or more viral vectors comprising nucleic acid, wherein the nucleic acid of said composition encodes a combination of tumor antigens, wherein said combination of tumor antigens consists of a GNAQ antigen, a TYRP1 antigen, and an N-RAS antigen, and wherein said GNAQ antigen, said TYRP1 antigen, and said N-RAS antigen are expressed from said viral vectors.

### Claim 2 (depends on 1)

The composition of claim 1, wherein said composition comprises a first viral vector encoding said GNAQ antigen, a second viral vector encoding said TYRP1 antigen, and a third viral vector encoding said N-RAS antigen.

### Claim 3

A method of treating cancer within a mammal, wherein said method comprises administering to said mammal a composition comprising one or more viral vectors comprising nucleic acid, wherein the nucleic acid of said composition encodes a combination of tumor antigens, wherein said combination of tumor antigens consists of a GNAQ antigen, a TYRP1 antigen, and an N-RAS antigen, and wherein said GNAQ antigen, said TYRP1 antigen, and said N-RAS antigen are expressed from said viral vectors.

### Claim 4 (depends on 3)

The method of claim 3, wherein said cancer is a melanoma.

### Claim 5 (depends on 3)

The method of claim 3, wherein said mammal is a human.

### Claim 6 (depends on 3)

The method of claim 3, wherein said composition comprises a first viral vector encoding said GNAQ antigen, a second viral vector encoding said TYRP1 antigen, and a third viral vector encoding said N-RAS antigen.